Immune Checkpoint Inhibitor-Associated Autoimmune Bullous Disease: A Clinical Review - PubMed
6 hours ago
- #Oncology Dermatology
- #Immune Checkpoint Inhibitors
- #Autoimmune Bullous Disease
- Immune checkpoint inhibitors (ICIs) used in cancer treatment can cause autoimmune bullous diseases like bullous pemphigoid and pemphigus vulgaris.
- ICI-induced bullous diseases resemble conventional autoimmune forms but may have delayed onset, mucosal involvement, and persist after stopping ICIs.
- Diagnosis involves clinical evaluation, histopathology, immunofluorescence, and ELISA tests.
- Treatment includes corticosteroids and immunosuppressants, with biologics like rituximab for refractory cases.
- Continuation of ICIs requires balancing cancer control with autoimmune toxicity, needing collaboration between dermatology and oncology teams.